论文部分内容阅读
目的 :探索抑癌基因P5 3基因的表达水平与卵巢肿瘤的临床和生物学行为之间是否存在一定的关系。方法 :应用免疫组化SP法检测P5 3在 71例卵巢上皮性肿瘤中的表达情况 ,并应用显微切割获取DNA和聚合酶链式反应 (PCR)—单链构象多态性分析 (SSCP)检测P5 3第 8外显子 (exon8)突变的情况。结果 :卵巢癌中P5 3蛋白阳性率为 5 1 6 % ,正常及交界性肿瘤中均为阴性 ,差异有极显著性意义 (P <0 0 0 1 )。P5 3蛋白阳性表达率在进展期 (Ⅲ/Ⅳ期 )较早期 (Ⅰ/Ⅱ期 )显著为高 ,差异有显著性意义 (P<0 0 5 )。P5 3表达水平与卵巢癌的组织学分级无关。结论 :P5 3蛋白表达异常在卵巢癌的进展过程中可能发挥有重要作用。卵巢癌中exon8可能不是P5 3的突变热点
Objective: To explore whether there is a relationship between the expression level of P53 gene and the clinical and biological behavior of ovarian tumors. Methods: Immunohistochemical SP method was used to detect the expression of P53 in 71 epithelial ovarian tumors. DNA and polymerase chain reaction (PCR) - single strand conformation polymorphism (SSCP) The mutation of P5 3 exon8 was detected. Results: The positive rate of P53 protein in ovarian cancer was 51.6%, which was negative in normal and borderline tumors, the difference was significant (P <0.01). The positive expression rate of P53 protein was significantly higher in the advanced stage (stage Ⅲ / Ⅳ) than in the early stage (stage Ⅰ / Ⅱ), the difference was significant (P <0.05). The expression of P53 was not related to the histological grade of ovarian cancer. Conclusion: The abnormal expression of P53 protein may play an important role in the progression of ovarian cancer. Exon8 in ovarian cancer may not be a hot spot for P5 3 mutation